219 related articles for article (PubMed ID: 33870733)
1. Sacubitril/valsartan treatment has differential effects in modulating diabetic kidney disease in
Myakala K; Jones BA; Wang XX; Levi M
Am J Physiol Renal Physiol; 2021 Jun; 320(6):F1133-F1151. PubMed ID: 33870733
[TBL] [Abstract][Full Text] [Related]
2. Sacubitril/valsartan inhibits obesity-associated diastolic dysfunction through suppression of ventricular-vascular stiffness.
Aroor AR; Mummidi S; Lopez-Alvarenga JC; Das N; Habibi J; Jia G; Lastra G; Chandrasekar B; DeMarco VG
Cardiovasc Diabetol; 2021 Apr; 20(1):80. PubMed ID: 33882908
[TBL] [Abstract][Full Text] [Related]
3. Insulinotropic Effects of Neprilysin and/or Angiotensin Receptor Inhibition in Mice.
Esser N; Schmidt C; Barrow BM; Cronic L; Hackney DJ; Mongovin SM; Hogan MF; Templin AT; Castillo JJ; Hull RL; Zraika S
Front Endocrinol (Lausanne); 2022; 13():888867. PubMed ID: 35733766
[TBL] [Abstract][Full Text] [Related]
4. Sacubitril/valsartan ameliorates renal tubulointerstitial injury through increasing renal plasma flow in a mouse model of type 2 diabetes with aldosterone excess.
Nishio H; Ishii A; Yamada H; Mori KP; Kato Y; Ohno S; Handa T; Sugioka S; Ishimura T; Ikushima A; Inoue Y; Minamino N; Mukoyama M; Yanagita M; Yokoi H
Nephrol Dial Transplant; 2023 Oct; 38(11):2517-2527. PubMed ID: 37202215
[TBL] [Abstract][Full Text] [Related]
5. Sacubitril/Valsartan Improves Diastolic Function But Not Skeletal Muscle Function in a Rat Model of HFpEF.
Schauer A; Adams V; Augstein A; Jannasch A; Draskowski R; Kirchhoff V; Goto K; Mittag J; Galli R; Männel A; Barthel P; Linke A; Winzer EB
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33808232
[TBL] [Abstract][Full Text] [Related]
6. Sacubitril/valsartan reduces susceptibility to atrial fibrillation by improving atrial remodeling in spontaneously hypertensive rats.
Li Q; Fang Y; Peng DW; Li LA; Deng CY; Yang H; Kuang SJ; Li QQ; Zhang MZ; Zeng P; Zhang QH; Liu Y; Deng H; Wei W; Xue YM; Wu SL; Rao F
Eur J Pharmacol; 2023 Aug; 952():175754. PubMed ID: 37182595
[TBL] [Abstract][Full Text] [Related]
7. Sacubitril/valsartan mitigates cardiac remodeling, systolic dysfunction, and preserves mitochondrial quality in a rat model of mitral regurgitation.
Tantisuwat L; Saengklub N; Boonpala P; Kumphune S; Panyasing Y; Kalandakanond-Thongsong S; Kijtawornrat A
Sci Rep; 2023 Jul; 13(1):11472. PubMed ID: 37455281
[TBL] [Abstract][Full Text] [Related]
8. Sacubitril/Valsartan inhibits M1 type macrophages polarization in acute myocarditis by targeting C-type natriuretic peptide.
Liu C; Long Q; Yang H; Yang H; Tang Y; Liu B; Zhou Z; Yuan J
Biomed Pharmacother; 2024 May; 174():116535. PubMed ID: 38581923
[TBL] [Abstract][Full Text] [Related]
9. Sacubitril/valsartan attenuates myocardial inflammation, hypertrophy, and fibrosis in rats with heart failure with preserved ejection fraction.
Shi YJ; Yang CG; Qiao WB; Liu YC; Liu SY; Dong GJ
Eur J Pharmacol; 2023 Dec; 961():176170. PubMed ID: 37939991
[TBL] [Abstract][Full Text] [Related]
10. Effect of sacubitril/valsartan on the hypertensive heart in continuous light-induced and lactacystin-induced pre-hypertension: Interactions with the renin-angiotensin-aldosterone system.
Simko F; Stanko P; Repova K; Baka T; Krajcirovicova K; Aziriova S; Domenig O; Zorad S; Adamcova M; Paulis L
Biomed Pharmacother; 2024 Apr; 173():116391. PubMed ID: 38461685
[TBL] [Abstract][Full Text] [Related]
11. Sacubitril/Valsartan contributes to improving the diabetic kidney disease and regulating the gut microbiota in mice.
Wang P; Guo R; Bai X; Cui W; Zhang Y; Li H; Shang J; Zhao Z
Front Endocrinol (Lausanne); 2022; 13():1034818. PubMed ID: 36589853
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety evaluation of sacubitril/valsartan in blood pressure control and clinical outcomes for elderly patients with heart failure and hypertension: A prospective cohort study.
Li X; Zuo C; Chen C; Tian D; Li J; Fan L; Li X; Lv Q
Int J Cardiol; 2023 Jan; 371():244-251. PubMed ID: 36174825
[TBL] [Abstract][Full Text] [Related]
13. Antiarrhythmic and Anti-Inflammatory Effects of Sacubitril/Valsartan on Post-Myocardial Infarction Scar.
Martínez-Falguera D; Aranyó J; Teis A; Ferrer-Curriu G; Monguió-Tortajada M; Fadeuilhe E; Rodríguez-Leor O; Díaz-Güemes I; Roura S; Villuendas R; Sarrias A; Bazan V; Delgado V; Bayes-Genis A; Bisbal F; Gálvez-Montón C
Circ Arrhythm Electrophysiol; 2024 May; 17(5):e012517. PubMed ID: 38666379
[TBL] [Abstract][Full Text] [Related]
14. Effect of Sacubitril/Valsartan on renal function in patients with chronic kidney disease and heart failure with preserved ejection fraction: A real-world 12-week study.
Jia R; Zhang X; Xu Y; Zheng Z; Jiang L; Zhang X; Sun C; Wu X; Li S; Raj A; Sun D
Eur J Pharmacol; 2022 Aug; 928():175053. PubMed ID: 35709921
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of low-dose sacubitril and/or valsartan on renal disease in salt-sensitive hypertension.
Polina I; Domondon M; Fox R; Sudarikova AV; Troncoso M; Vasileva VY; Kashyrina Y; Gooz MB; Schibalski RS; DeLeon-Pennell KY; Fitzgibbon WR; Ilatovskaya DV
Am J Physiol Renal Physiol; 2020 Jul; 319(1):F63-F75. PubMed ID: 32463726
[TBL] [Abstract][Full Text] [Related]
16. TaleNeprilysin and Neprilysin inhibition in chronic kidney disease.
Judge PK; Haynes R
Curr Opin Nephrol Hypertens; 2021 Jan; 30(1):123-130. PubMed ID: 33148948
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of sacubitril/valsartan for patients with hypertension and heart failure in the real-world setting: A retrospective study in China.
Zuo C; Li X; Fan L; Li J; Tian D; Chen C; Li X; Lv Q
J Clin Pharm Ther; 2022 Oct; 47(10):1539-1547. PubMed ID: 35649528
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Assessment of Combination Therapy with a Neprilysin Inhibitor and Angiotensin Type 1 Receptor Antagonist on Angiotensin II-Induced Atherosclerosis, Abdominal Aortic Aneurysms, and Hypertension.
AlSiraj Y; Thatcher SE; Liang CL; Ali H; Ensor M; Cassis LA
J Pharmacol Exp Ther; 2021 Jun; 377(3):326-335. PubMed ID: 33707301
[TBL] [Abstract][Full Text] [Related]
19. LCZ696 (Sacubitril/Valsartan), an Angiotensin-Receptor Neprilysin Inhibitor, Attenuates Cardiac Hypertrophy, Fibrosis, and Vasculopathy in a Rat Model of Chronic Kidney Disease.
Suematsu Y; Jing W; Nunes A; Kashyap ML; Khazaeli M; Vaziri ND; Moradi H
J Card Fail; 2018 Apr; 24(4):266-275. PubMed ID: 29325796
[TBL] [Abstract][Full Text] [Related]
20. Heart failure signs and symptoms, hospital referrals, and prescription patterns in patients receiving sacubitril/valsartan in primary care and cardiologist settings in Germany.
Wachter R; Klebs S; Balas B; Kap E; Engelhard J; Schlienger R; Bruce Wirta S; Fonseca AF
ESC Heart Fail; 2020 Oct; 7(5):2318-2330. PubMed ID: 33121216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]